Gossamer Bio Inc. (NASDAQ: GOSS)
$1.19
-0.0600 ( -4.80% ) 578.7K
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Market Data
Open
$1.19
Previous close
$1.25
Volume
578.7K
Market cap
$268.07M
Day range
$1.18 - $1.32
52 week range
$0.45 - $1.88
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Dec 05, 2023 |
3 | Insider transactions | 2 | Dec 05, 2023 |
4 | Insider transactions | 1 | Nov 29, 2023 |
8-k | 8K-related | 14 | Nov 29, 2023 |
3 | Insider transactions | 2 | Nov 29, 2023 |
8-k | 8K-related | 14 | Nov 27, 2023 |
4 | Insider transactions | 1 | Nov 22, 2023 |